AACR-2022- NI2601 and NI-2901 CD47xPD-L1 bispecific antibodies

On April 4, 2022 The American Association for Cancer Research (AACR) (Free AACR Whitepaper) reported that it will host its Annual Meeting April 8-13, 2022. Light Chain Bioscience is very pleased to have Xavier Chauchet attend in-person (Presentation, Light Chain Bioscience, APR 4, 2022, View Source [SID1234611437]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Xavier will be presenting two posters #3225 and #3283 describing differentiating CD47xPD-L1 bispecific #antibody approaches, NI-2601 & NI-2901.

"NI-2601, an Fc-active CD47xPD-L1 bispecific antibody that selectively targets CD47 on PD-L1-positive tumors" (#3283) will be exposed and presented on April 12 between 1:30-5:00 p.m.

↠ Read 1st poster – Poster section 32 : Will be available on website from April 9th.

"NI-2901, a CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade with fine-tuned affinity to reduce erythrocyte binding and improve biodistribution" (#3225) will be exposed and presented on April 12 between 1:30-5:00 p.m.

:↠ Read 2nd poster – Poster section 32 :Will be available on website from April 9th.

Ernest N. Morial Convention Center New Orleans, Louisiana

900 Convention Center Blvd, New Orleans, LA 70130, United States